top of page

APAC Regional Overview

Advantages of conducting clinical research in the Asia Pacific Region:

•Favorable study start-up timelines which are 4-6 months for clinical trial approvals (Note: Recently, the China Center for Drug Evaluation (CDE) has increase the number of reviewers, from 100 in 2015 to more than 600 in 2018, which has significantly reduced the (historical) application backlog from an average of 4.49 years in 2015 to just 53 days in 2018).

•Ease of subject recruitment which is driven by large treatment naive populations.  APAC population exceeds 4  billion

•Fewer competing clinical trials than in the west

•The ability to obtain experienced and highly educated/trained personnel to support the conduct of clinical research

•Access to lower cost infrastructure and labor pools. Often costs are 30% to 50% less than in the west


Regional Harmonization:

•The Association of Southeast Asian Nations (ASEAN) is comprised of ten member nations, forming the world's third largest population with 622 million people in 2014.

•The 10 member states of ASEAN and the ASEAN Economic Community (AEC): Indonesia, Malaysia, Philippines, Singapore, Thailand, Brunei, Cambodia, Laos, Myanmar (Burma) and Vietnam.

•ASEAN members states anticipate regional harmonization of clinical research regulatory requriements.



CLINIQAL International supports the growing demand for regional CROs by filling a niche market which provides expert Clinical Quality Assurance and Regulatory Compliance project management and auditing services.  The company is based centrally in Thailand which affords the advantage of being roughly four (4) hours from all major Asia Pacific (APAC) locations namely:

  • Japan, South Korea and Taiwan

  • China/Hong Kong

  • India and Nepal

  • Southeast Asia – Mainland region to include: Thailand, Vietnam, Cambodia, Laos and Myanmar (Burma) and the Maritime region to include: Singapore, Malaysia, Indonesia, and Philippines





bottom of page